ly3541860
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 11, 2021 (NCT05042310)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06859294 | Phase 2 | Mar 31, 2025 | Eli Lilly |
| NCT06220669 | Phase 2 | Mar 19, 2024 | Eli Lilly |
| NCT05042310 | Phase 1 | Nov 11, 2021 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 2 | 2021 |
1 organizations
Page 1 / 1